|
2023 Journal Article Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management frameworkPatel, Nishal, Mehawed, Georges, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Chung, Eric, Tse, Vincent and Roberts, Matthew J. (2023). Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework. Urology, 178, 1-8. doi: 10.1016/j.urology.2023.05.002 |
|
2023 Journal Article A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsyKelly, Brian D., Ptasznik, Gideon, Roberts, Matthew J., Doan, Paul, Stricker, Phillip, Thompson, James, Buteau, James, Chen, Kenneth, Alghazo, Omar, O'Brien, Jonathan S., Hofman, Michael S., Frydenberg, Mark, Lawrentschuk, Nathan, Lundon, Dara, Murphy, Declan G., Emmett, Louise and Moon, Daniel (2023). A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy. European Urology Open Science, 53, 90-97. doi: 10.1016/j.euros.2023.05.002 |
|
2023 Conference Publication Lu-PSMA Therapy - Practical considerations for urologistsCollin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Lu-PSMA Therapy - Practical considerations for urologists. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James, Moon, Daniel, Fahey, Michael, Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Dilulio, Juliana, Lindeman, William, De Abreu, Lourenco Richard, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Can artificial intelligence devise surveillance regimens for testicular cancer?Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Can artificial intelligence devise surveillance regimens for testicular cancer?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Dr Bot - Does AI provide quality information to prostate cancer patients?Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Dr Bot - Does AI provide quality information to prostate cancer patients?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New ZealandO' Callaghan, Michael E., Roberts, Matthew, Grummet, Jeremy, Mark, Stephen, Gilbourd, Daniel, Frydenberg, Mark, Millar, Jeremy and Papa, Nathan (2023). Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand. Urologic Oncology: Seminars and Original Investigations, 41 (7), 324.e13-324.e20. doi: 10.1016/j.urolonc.2023.05.011 |
|
2023 Conference Publication Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND TrialRoberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Journal Article Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?Keogh, Kandice, Collin, Harry, Dowling, Caroline and Roberts, Matthew J. (2023). Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?. BJU International, 133 (S3), 6-7. doi: 10.1111/bju.16096 |
|
2023 Journal Article Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic reviewTariq, Arsalan, Stewart, Adam G., Desai, Devang J., Britton, Sumudu, Dunglison, Nigel, Esler, Rachel and Roberts, Matthew J. (2023). Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review. Current Urology, 17 (2), 100-108. doi: 10.1097/cu9.0000000000000159 |
|
2023 Conference Publication Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.16_suppl.TPS4617 |
|
2023 Journal Article Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?Roberts, Matthew J., Hruby, George, Kneebone, Andrew, Martin, Jarad M., Williams, Scott G., Frydenberg, Mark, Murphy, Declan G., Namdarian, Ben, Yaxley, John W., Hofman, Michael S., Davis, Ian D. and Emmett, Louise (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. BJU International, 132 (2), 146-148. doi: 10.1111/bju.16086 |
|
2023 Journal Article Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancerDoan, Paul, Counter, William, Papa, Nathan, Sheehan‐Dare, Gemma, Ho, Bao, Lee, Jonathan, Liu, Victor, Thompson, James E., Agrawal, Shikha, Roberts, Matthew J., Buteau, James, Hofman, Michael S., Moon, Daniel, Lawrentschuk, Nathan, Murphy, Declan, Stricker, Phillip D. and Emmett, Louise (2023). Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer. BJU International, 131 (5), 588-595. doi: 10.1111/bju.15929 |
|
2023 Journal Article Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can workMehawed, Georges, Ranasinghe, Sachinka and Roberts, Matthew J. (2023). Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work. Urology Case Reports, 47 102356, 1-3. doi: 10.1016/j.eucr.2023.102356 |
|
2023 Conference Publication PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, Lourenco, Richard De Abreu, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. Genitourinary Cancers Symposium, Electr Network, 16-18 February 2023. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2023.41.6_suppl.TPS397 |
|
2023 Conference Publication PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, De Abreu Lourenço, Richard, Dhillon, Haryana M., Hofman, Michael S and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps397 |
|
2023 Conference Publication Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trialKasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S. and Hofman, M.S. (2023). Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial. EAU23 - 38th Annual EAU Congress, Milan, Italy, 10-13 March 2023. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(23)01275-7 |
|
2023 Journal Article Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?Robinson, Harley, Roberts, Matthew J., Gardiner, Robert A. and Hill, Michelle M. (2023). Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?. Seminars in Cancer Biology, 89, 18-29. doi: 10.1016/j.semcancer.2023.01.003 |
|
2023 Journal Article Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based studyO'Callaghan, Michael E., Roberts, Matthew J., Moretti, Kim L., Frydenberg, Mark, Gilbourd, Daniel, Mark, Stephen, Heathcote, Peter, Millar, Jeremy, PCOR-ANZ and Papa, Nathan (2023). Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study. Urologic Oncology: Seminars and Original Investigations, 41 (2), 105.e9-105.e18. doi: 10.1016/j.urolonc.2022.10.020 |
|
2023 Journal Article Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?McGeorge, Stephen, Loh, Brendon, Shibu, Ryan, Dobeli, Karen, Brown, Nathan J., Esler, Rachel, Hacking, Craig, Purvey, Megan and Roberts, Matthew J. (2023). Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?. BJUI Compass, 4 (1), 59-61. doi: 10.1002/bco2.192 |
